A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia

Leukemia

Volumn 14, Issue 4, 2000, Pages 754-766

  Pfitzner, T ^a   Engert, A ^a   Wittor, H ^b   Schinkothe T ^d   Oberhauser F ^a   Schulz, H ^a   Diehl, V ^a   Barth, S ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d NONE

Author keywords

Chronic lymphatic leukemia; Minimal residual disease; Real time quantitative PCR

Indexed keywords

FLUORESCENT DYE; IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; ASSAY; B CELL LYMPHOMA; CASE REPORT; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

EID: 0034034410     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401706     Document Type: Article

References (32)

1. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25: 65-74.
2. Czuczman M, Grillo-Lopez, AJ, McLaughlin P, Link BK, Rogers J, Cabanillas F, White CA, Shen CD, Varns C. IDEC-C2B8 clears bcl-2 (t14; 18) in patients (pts) with relapsed low grade or follicular lymphoma (LG/F NHL) (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1997.
3. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis oin a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77: 89-91.
4. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Severe cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-2224.
5. Roberts W, Estrov Z, Zipt T. Detection of minimal residual disease in acute lymphoblastic leukemia (letter; comment). Blood 1995; 86: 1237-1239.
6. Maloum K, Pritsch O, Dighiero G. Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Hematol Cell Ther 1997; 39: 119-124.
7. Schultze JL, Donovan JW, Gribben JG. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphytic leukemia. J Mol Med 1999; 77: 259-265.
8. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction (see comments). Lancet 1994; 343: 196-200.
9. Lin F, Goldman J, Cross N. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia (see comments). Br J Haematol 1994; 86: 683-685.
10. Cross N. Quantitative PCR techniques and applications. Br J Haematol 1995; 89: 693-697.
11. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AMLI/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482-1489.
12. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998; 58: 3957-3964.
13. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5′ exonuclease-based real-time PCR assay for the detection of t (14; 18)(q32; q21) in patients with follicular lymphoma. Am J Pathol 1998; 153: 63-68.
14. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
15. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997; 22: 130-131, 134-138.
16. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.
17. Corradini P, Voena C, Omede P, Astolfi M, Boccadoro M, Dalla-Favera R, Pileri A. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7: 1879-1882.
18. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596-1602.
19. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
20. Diehl V, Kirchner HH, Burrichter H. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rev 1982; 66: 615-632.
21. Higuchi R. Simple and Rapid Preparation of Samples for PCR, In: Erlich HA (ed). PCR Technology. Stockton Press: New York, 1989, pp 31-38.
22. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996; 88: 3314-3322.
23. Kueppers R, Hansmann ML, Rajewsky K. Micromanipulation and PCR analysis of single cells from tissue sections, In: Herzenberg LA, Weir D, Blackwell D (eds). Handbook of Experimental Immunology. Blackwell Science: Oxford, 1997, p 4.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY; 1989.
25. Wang Z, Spadoro J. Determination of target copy number of quantitative standards used in PCR-based diagnostic assays. In: Ferre F (ed). Gene Quantification. Birkhäuser: Boston, pp 33-43.
26. Breslauer KJ, Frank R, Blocker H, Marky LA. Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci USA 1986; 83: 3746-3750.
27. Jeffreys AJ, Wilson V, Neumann R, Keyte J. Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. Nucleic Acids Res 1988; 16: 10953-10971.
28. Lankowicz JR. Energy transfer. In: Principles of Fluorescent Spectroscopy. Plenum Press: New York, 1989, pp. 303-339.
29. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
30. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved (see comments). Leukemia 1995; 9: 321-328.
31. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
32. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.